TS-ONE
  • About TS-ONE ®
  • Patient Information
  • Useful Information
  • Contact

  • 1. What’s TS-ONE ®

  • 2. Approved Countries

  • 3. Scientific Information

  • 4. Administration

Phase III Studies and Guideline Recommendations*


Gastric Cancer

Colorectal Cancer

Pancreatic Cancer

Biliary Tract Cancer

Lung Cancer

Breast Cancer

Head and Neck Cancer


* In Hong Kong, TS-ONE ® is indicated for post operative adjuvant chemotherapy for locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer 2.

Pancreatic Cancer
  • Motoi F et al., 2019. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/ JSAP-05).
    Jpn J Clin Oncol., 49(2), pp.190-194.
  • Okusaka T. et al. 2020 Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis.
    Pancreas. 2020 Mar; 49(3):326-335
  • Uesaka K et al., 2016. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label randomised, non-inferiority trial (JASPAC 01).
    Lancet, 388(10041), pp.248-257.
  • Ueno H et al., 2013. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
    J Clin Oncol., 31(13), pp.1640-1648.




This Site is intended for Hong Kong healthcare professionals only. Products discussed herein may have different labeling in different countries. TS-ONE® is a registered trademark of TAIHO PHARMACEUTICAL CO., LTD. and used under license. Copyright © TAIHO PHARMACEUTICAL CO., LTD. 2020 All rights reserved.